EyebioKorea, Inc. clinical trials
Acquired by Merck & Co., Inc, Jul 2024 · source ↗
The registry lists 2 studies whose lead sponsor is EyebioKorea, Inc. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 27, 2024.
- 2studies on the registry
- 1open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before EyebioKorea, Inc. became part of Merck & Co., Inc
- 2
- First submitted after EyebioKorea, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 122
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- EyebioKorea, Inc.2 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Merck & Co., Inc studies →
- Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular DegenerationRecruitingNCT06487039Phase 2
Sponsor listed in the registry: EyebioKorea, Inc. · First submitted before EyebioKorea, Inc. became part of Merck & Co., Inc
- Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy VolunteersCompletedNCT05538949Phase 1
Sponsor listed in the registry: EyebioKorea, Inc. · First submitted before EyebioKorea, Inc. became part of Merck & Co., Inc